Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
AbbVie scales back its GARP ambitions
After a phase 3 push the livmoniplimab plan falters.
Like MacroGenics, Sanofi tries to square an uneasy circle
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
China’s latest Car-T bets revealed
First-in-human listings bring a bispecific and yet another in vivo Car-T.
A first for CCR8
Cafelkibart’s entry into phase 3 is of note to Coherus.
Sanofi steps back from radioconjugates
The company quietly deprioritises AlphaMedix.
The month ahead: February’s upcoming events
Tecvayli and Hernexeos might get speedy approval decisions.
Revolution adds to its KRAS ambitions
RMC-5127 becomes the company’s fourth clinical project.
ImmuneOnco takes a second project pivotal
The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
